Binding kinetics, bias, receptor internalization and effects on insulin secretion in vitro and in vivo of a novel <scp>GLP</scp> ‐ <scp>1R</scp> / <scp>GIPR</scp> dual agonist, <scp>HISHS</scp> ‐2001
HISHS-2001 represents a novel dual receptor agonist with a promising pharmacological profile and actions. Future clinical studies will be needed to assess the safety and efficacy of this molecule in humans.
Authors
- Piero Marchetti (ORCID: https://orcid.org/0000-0003-4907-0635)
- Muthukumaran Natarajan
- Isabelle Leclerc (ORCID: https://orcid.org/0000-0003-0044-7921)
- Guy A. Rutter (ORCID: https://orcid.org/0000-0001-6360-0343)
- Zenouska Ramchunder (ORCID: https://orcid.org/0009-0008-0194-2311)
- Vinod Burade (ORCID: https://orcid.org/0009-0008-3710-3667)
- Yusman Manchanda (ORCID: https://orcid.org/0000-0002-2874-5608)
- Ben Jones (ORCID: https://orcid.org/0000-0003-0461-2584)
- Gaëlle Carrat (ORCID: https://orcid.org/0000-0003-1189-3441)
- Alejandra Tomás (ORCID: https://orcid.org/0000-0002-2290-8453)
- Pradeep Shahi
- Rajamannar Thennati
Institutions
- University of Pisa (IT)
- Nanyang Technological University (SG)
- McGill University Health Centre (CA)
- Sun Pharma Advanced Research (India) (IN)
- Centre Hospitalier de l’Université de Montréal (CA)
- Imperial College London (GB)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-08-20
- DOI
- https://doi.org/10.1111/dom.16652
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Eli Lilly and Company
- Wellcome Trust
- Canada Foundation for Innovation
- Diabetes UK
- Society for Endocrinology
- National Institutes of Health
- Canadian Institutes of Health Research
- Medical Research Council
- National Institute of Diabetes and Digestive and Kidney Diseases
- Institute of Nutrition, Metabolism and Diabetes
- Division of Diabetes, Endocrinology, and Metabolic Diseases